Stories about: ProVision

Howard Florey researchers say mental and physical stimulation delays onset of dementia in Huntington's mice.

How did a chemistry PhD become one of the 50 most powerful women in business by hooking up the world's largest computer company with the life sciences? Kate McDonald spoke to IBM's Carol Kovac, who admits to being rather excited about the world of biology.

Australia's Nanostructural Analysis Network Organisation (NANO) was established four years ago to provide top-tier microscopy services for Australian scientists.

Psiron (ASX:PSX) has moved to reassure shareholders of its ability to fund its business plans, in the wake of last week's resignations of the company's CEO and CFO.

The CEO of Melbourne company Biota Holdings (ASX:BTA), Peter Cook, believes GlaxoSmithKline is using delaying tactics in the current court case before the Victorian courts, in which Biota is suing GSK for up to AUD$430 million.

Ruth Beran wraps up a recent report that gives Australia a high rating against other major centres of pharma R&D.

Resonance Health Analysis Services (RHAS), a subsidiary of Perth-based Resonance Health (ASX:RHT), has been awarded a health supply contract from the government of Western Australia's department of health, for its FerriScan diagnostic test.

Resonance Health Group (ASX:RHT) has signed a memorandum of understanding with a US radiology service provider for a pilot study in preparation for the commercial launch of its FerriScan diagnostic test.

NeuroSolutions, a subsidiary of newly listed neurology-focused biotech company NeuroDiscovery (ASX:NDL) has entered into a collaborative agreement with Epichem, a subsidiary of PharmAust (ASX:PAA) to assist with the development of one of NeuroSolutions' lead pain drug candidates, NSL-036.

Artificial heart company Ventracor (ASX:VCR) has posted a net loss of $AUD26.6 million for 2004-05, up 68 per cent from $15.9 million in the previous financial year.